TGFBI and ovarian carcinoma: MiR-23b has been shown to downregulate the expression of integrin β3 by targeting the histone methyltransferase EZH2, which represses integrin β3 transcription (an integrin known for transforming growth factor beta-induced (TGFBI) function and paclitaxel response in ovarian cancer cells) by promoting the H3K27 trimethylation of the integrin β3 promoter [59,60].